高级检索

血钙、25-羟维生素D及尿酸水平与良性阵发性位置性眩晕的相关性研究

Correlations of serum calcium, 25-hydroxyvitamin D and uric acid levels with benign paroxysmal positional vertigo

    摘要
  • 摘要:
    目的 探讨血钙、25-羟维生素D及尿酸水平与良性阵发性位置性眩晕(BPPV)的相关性。
    方法 选取96例BPPV患者纳入眩晕组, 依据眩晕严重程度的不同进一步分为轻度眩晕组30例、中度眩晕组42例和重度眩晕组24例，另选取63例无BPPV的健康体检人员纳入对照组。比较各组研究对象的血钙、25-羟维生素D及尿酸水平，分析血钙、25-羟维生素D及尿酸水平与BPPV患者眩晕严重程度的相关性。随访3个月，统计BPPV患者复发率。
    结果 中度眩晕组、重度眩晕组的血钙、25-羟维生素水平均低于轻度眩晕组和对照组，尿酸水平和眩晕障碍量表(DHI)总分及功能、情感、躯体维度评分均高于轻度眩晕组和对照组，差异有统计学意义(P < 0.05); 重度眩晕组的血钙、25-羟维生素水平均低于中度眩晕组，尿酸水平和DHI总分及功能、情感、躯体维度评分高于中度眩晕组，差异有统计学意义(P < 0.05); 轻度眩晕组的血钙、25-羟维生素、尿酸水平和DHI评分与对照组比较，差异无统计学意义(P>0.05)。BPPV患者眩晕严重程度与血钙、25-羟维生素D水平呈负相关(r=-0.557、-0.467, P < 0.05), 与尿酸水平呈正相关(r=0.504, P < 0.05)。BPPV患者3个月内复发率为8.33%(8/96); 与血钙≥2.11 mmol/L、25-羟维生素D≥30 ng/mL、尿酸≤428 μmol/L的患者分别比较，血钙 < 2.11 mmol/L、25-羟维生素D < 30 ng/mL、尿酸>428 μmol/L的患者BPPV复发率均更高，差异有统计学意义(P < 0.05)。
    结论 BPPV患者血钙、25-羟维生素D水平异常降低，尿酸水平异常升高。BPPV患者眩晕严重程度与血钙、25-羟维生素D水平呈负相关，与尿酸水平呈正相关。

     

    Abstract:
    Objective To investigate the correlations of serum calcium, 25-hydroxyvitamin D and uric acid levels with benign paroxysmal positional vertigo (BPPV).
    Methods A total of 96 patients with BPPV were enrolled in vertigo group and further divided into mild vertigo (30 cases), moderate vertigo (42 cases), and severe vertigo (24 cases) groups based on the severity of vertigo symptoms. Additionally, 63 healthy people undergoing physical examination without BPPV were recruited as control group. Serum calcium, 25-hydroxyvitamin D, and uric acid levels were compared among groups, and their correlations with the severity of vertigo in BPPV patients were analyzed. Follow-up was conducted for 3 months to record the recurrence rate of BPPV.
    Results The serum calcium and 25-hydroxyvitamin D levels in the moderate and severe vertigo groups were significantly lower, while uric acid levels, total score of Dizziness Handicap Inventory (DHI) as well as functional, emotional, and physical scores were significantly higher than those in the mild vertigo group and control group (P < 0.05). Moreover, the severe vertigo group exhibited lower serum calcium and 25-hydroxyvitamin D levels and higher uric acid level, DHI total score and functional, emotional, as well as physical scores (P < 0.05). No significant differences were observed in serum calcium, 25-hydroxyvitamin D, uric acid levels, or DHI scores between the mild vertigo group and the control group (P>0.05). The severity of vertigo in BPPV patients was negatively correlated with serum calcium (r=-0.557, P < 0.05) and 25-hydroxyvitamin D levels (r=-0.467, P < 0.05), and positively correlated with uric acid levels (r=0.504, P < 0.05). The 3-month recurrence rate of BPPV was 8.33%(8/96). Compared to patients with serum calcium ≥2.11 mmol/L, 25-hydroxyvitamin D ≥30 ng/mL, and uric acid ≤428 μmol/L, those with serum calcium < 2.11 mmol/L, 25-hydroxyvitamin D < 30 ng/mL, and uric acid >428 μmol/L had significantly higher BPPV recurrence rates (P < 0.05).
    Conclusion BPPV patients exhibit abnormally lower serum calcium and 25-hydroxyvitamin D levels and abnormally higher uric acid levels. The severity of vertigo in BPPV patients is negatively correlated with serum calcium and 25-hydroxyvitamin D levels and positively correlated with uric acid levels.

     

    • HTML全文
    • 参考文献(14)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回